David Mysona

661 total citations
25 papers, 419 citations indexed

About

David Mysona is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, David Mysona has authored 25 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Oncology and 8 papers in Reproductive Medicine. Recurrent topics in David Mysona's work include Ovarian cancer diagnosis and treatment (8 papers), Endometrial and Cervical Cancer Treatments (5 papers) and PARP inhibition in cancer therapy (4 papers). David Mysona is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), Endometrial and Cervical Cancer Treatments (5 papers) and PARP inhibition in cancer therapy (4 papers). David Mysona collaborates with scholars based in United States, Italy and Peru. David Mysona's co-authors include Jin‐Xiong She, Ashok Sharma, Shan Bai, John L. Wagner, Nathan D. Smith, Sharad Ghamande, Bunja Rungruang, Sharad Purohit, Lynn Tran and Richard D. Cummings and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Scientific Reports.

In The Last Decade

David Mysona

25 papers receiving 416 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Mysona United States 9 202 112 104 69 57 25 419
Cécile Blanc‐Fournier France 13 139 0.7× 96 0.9× 117 1.1× 71 1.0× 24 0.4× 26 330
M. Koukourakis Greece 12 284 1.4× 125 1.1× 227 2.2× 96 1.4× 65 1.1× 28 563
Evangelos Bournakis Greece 15 272 1.3× 153 1.4× 267 2.6× 45 0.7× 39 0.7× 35 621
Arpita Desai United States 10 229 1.1× 116 1.0× 165 1.6× 33 0.5× 31 0.5× 38 451
Junli Deng China 7 332 1.6× 180 1.6× 198 1.9× 33 0.5× 55 1.0× 8 498
Dawo Liu China 18 456 2.3× 174 1.6× 132 1.3× 56 0.8× 187 3.3× 30 665
Marta Cesca Italy 11 233 1.2× 126 1.1× 161 1.5× 33 0.5× 23 0.4× 14 465
Marta Sesé Spain 10 444 2.2× 232 2.1× 173 1.7× 55 0.8× 86 1.5× 18 742
Chae Young Han Canada 11 399 2.0× 225 2.0× 98 0.9× 14 0.2× 47 0.8× 13 593
Katharina Malinowsky Germany 17 389 1.9× 177 1.6× 149 1.4× 124 1.8× 55 1.0× 27 660

Countries citing papers authored by David Mysona

Since Specialization
Citations

This map shows the geographic impact of David Mysona's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Mysona with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Mysona more than expected).

Fields of papers citing papers by David Mysona

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Mysona. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Mysona. The network helps show where David Mysona may publish in the future.

Co-authorship network of co-authors of David Mysona

This figure shows the co-authorship network connecting the top 25 collaborators of David Mysona. A scholar is included among the top collaborators of David Mysona based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Mysona. David Mysona is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vernon, Marlo, Bunja Rungruang, Robert V. Higgins, et al.. (2024). Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes. Gynecologic Oncology. 189. 129–136. 4 indexed citations
2.
Mysona, David, et al.. (2024). Serum Proteomic Signatures in Cervical Cancer: Current Status and Future Directions. Cancers. 16(9). 1629–1629. 2 indexed citations
3.
Mysona, David, Bunja Rungruang, Diane Hopkins, et al.. (2023). High serum levels of inflammatory markers are associated with early recurrence in patients with high-grade serous ovarian cancer after platinum therapy. Gynecologic Oncology. 179. 1–8. 2 indexed citations
4.
Mysona, David, Sharad Purohit, Bunja Rungruang, et al.. (2023). Ovarian recurrence risk assessment using machine learning, clinical information, and serum protein levels to predict survival in high grade ovarian cancer. Scientific Reports. 13(1). 20933–20933. 5 indexed citations
5.
Somasegar, Sahana, Susan M. Lang, David Mysona, et al.. (2023). Differences in the mutational landscape directing targeted therapies for Black and White patients with endometrial cancer (2113). Gynecologic Oncology. 176. S205–S205. 1 indexed citations
6.
7.
Mysona, David, et al.. (2021). The elusive diagnosis and emergent management of a late-presenting ruptured interstitial pregnancy: a case report. BMC Pregnancy and Childbirth. 21(1). 553–553. 4 indexed citations
8.
Mysona, David, Mary Kathryn Abel, Kathleen M. Darcy, et al.. (2021). Racial disparities in prevalence of homologous recombination deficiency in ovarian, uterine, and cervical cancer tumors. Gynecologic Oncology. 162. S45–S46. 1 indexed citations
9.
Mysona, David, Daniel S. Kapp, Amandeep Mann, et al.. (2021). Applying Artificial Intelligence to Gynecologic Oncology: A Review. Obstetrical & Gynecological Survey. 76(5). 292–301. 19 indexed citations
10.
Richardson, Michael, David Mysona, David A. Klein, et al.. (2020). Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit. Gynecologic Oncology. 159(1). 118–128. 8 indexed citations
11.
Tian, Chunqiao, Michael Richardson, John K. Chan, et al.. (2020). Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities. Gynecologic Oncology. 157(1). 121–130. 9 indexed citations
12.
Mysona, David, Sharad Ghamande, Jin‐Xiong She, et al.. (2020). Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?. Annals of Surgical Oncology. 28(7). 3605–3615. 5 indexed citations
13.
Tran, Lynn, David Mysona, Sharad Purohit, et al.. (2020). A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy. Gynecologic Oncology. 157(2). 340–347. 4 indexed citations
14.
Purohit, Sharad, Daron G. Ferris, Lynn Tran, et al.. (2020). Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy. Gynecologic Oncology. 157(1). 181–187. 9 indexed citations
15.
Wagner, John L., David Mysona, Nathan D. Smith, et al.. (2019). A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. BMC Cancer. 19(1). 581–581. 217 indexed citations
16.
Mysona, David, Lynn Tran, Paola A. Gehrig, et al.. (2019). Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers. Gynecologic Oncology. 156(1). 77–84. 12 indexed citations
17.
Purohit, Sharad, Tiehai Li, Wanyi Guan, et al.. (2018). Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins. Nature Communications. 9(1). 258–258. 61 indexed citations
18.
Mysona, David, Sharad Purohit, Wenbo Zhi, et al.. (2018). A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer. Gynecologic Oncology. 152(3). 574–580. 25 indexed citations
19.
20.
Mysona, David, Shan Bai, Ashok Sharma, et al.. (2016). MMP-7 a potential biomarker of invasive cervix cancer: A prospective pilot study.. Journal of Clinical Oncology. 34(15_suppl). e17005–e17005. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cécile Blanc‐Fournier Breakdown of academic impact, for papers by M. Koukourakis Breakdown of academic impact, for papers by Evangelos Bournakis Breakdown of academic impact, for papers by Arpita Desai Breakdown of academic impact, for papers by Junli Deng Breakdown of academic impact, for papers by Dawo Liu Breakdown of academic impact, for papers by Marta Cesca Breakdown of academic impact, for papers by Marta Sesé Breakdown of academic impact, for papers by Chae Young Han Breakdown of academic impact, for papers by Katharina Malinowsky
Rankless by CCL
2026